Vivos Therapeutics announced an expanded partnership with Greenway Health to deploy its AI-powered Novare platform, projecting up to $9.1 million in annual value creation and $1.8 million in cost savings from increased efficiency at its Sleep Centers of Nevada. This initiative aims to boost patient capacity and improve revenue cycles, potentially leading to significant operating leverage for the company.
Vivos Therapeutics has expanded its strategic engagement with Greenway Health to implement the AI-by-design Novare platform across its clinical operations, starting with Sleep Centers of Nevada. This move is significant because Greenway's analysis estimates substantial financial benefits for Vivos, including up to $9.1 million in annual value creation from increased patient capacity and revenue cycle improvements, plus an additional $1.8 million in annual savings from recovered labor hours. This could lead to meaningful operating leverage and improved profitability for Vivos, making it a positive development for the company's long-term growth prospects. For traders, this presents an opportunity to consider the potential for improved financial performance and operational efficiency for VVOS, though the 'potential' and 'estimates' nature of the figures should be noted.